Sienna Biopharmaceuticals, a clinical-stage biotech developing topical therapies for dermatological conditions, filed on Monday with the SEC to raise up to $75 million in an initial public offering.
The Westlake Village, CA-based company was founded in 2010 and plans to list on the Nasdaq under the symbol SNNA. Sienna Biopharmaceuticals filed confidentially on May 15, 2017. J.P. Morgan, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
